<- Go Home
SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Market Cap
$233.4M
Volume
495.1K
Cash and Equivalents
$10.5M
EBITDA
-$45.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$33.4M
Profit Margin
N/A
52 Week High
$6.60
52 Week Low
$1.00
Dividend
N/A
Price / Book Value
1.44
Price / Earnings
-5.77
Price / Tangible Book Value
1.44
Enterprise Value
$142.7M
Enterprise Value / EBITDA
-3.56
Operating Income
-$49.0M
Return on Equity
14.96%
Return on Assets
-28.20
Cash and Short Term Investments
$96.6M
Debt
$6.0M
Equity
$151.5M
Revenue
N/A
Unlevered FCF
-$22.1M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium